World Heart to complete initial testing soon
This article was originally published in Clinica
World Heart, a Canadian developer of an artificial heart, expects to complete in vitro and animal testing of its first product, the HeartSaver VAD, by the middle of the year. The company based in Ottawa, Ontario, raised $19 million in its initial public offering last year. The HeartSaver is the first pulsatile ventricular assist device (VAD) designed to be permanently implanted in the chest cavity alongside the natural heart. Pilot production of prototypes and long-term animal testing is expected to begin before the end of the year. Clinical trials are scheduled for 1999.
You may also be interested in...
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.